Cardinal Health
CAH
$215.13
+1.11%
Cardinal Health, Inc. is a major player in the healthcare industry, operating as one of the three leading pharmaceutical wholesalers in the United States. Its core business involves sourcing and distributing branded, generic, and specialty pharmaceutical products to a vast network of pharmacies, hospital networks, and healthcare providers, while also supplying medical-surgical products and equipment globally. The company holds a dominant market position as part of an oligopoly, alongside Cencora and McKesson, controlling well over 90% of the US pharmaceutical wholesale market, which provides significant scale and competitive moat. The current investor narrative centers on the company's ability to navigate the low-margin, high-volume wholesale distribution model while demonstrating consistent profitability and cash generation, with recent attention likely focused on its quarterly dividend approval reinforcing its status as a stable income stock within the defensive healthcare sector.…
CAH
Cardinal Health
$215.13
Related headlines
Investment Opinion: Should I buy CAH Today?
Rating: Hold. The core thesis is that Cardinal Health is a high-quality, defensive business trading at a full valuation after a powerful rally, making the risk/reward balanced at current levels.
Supporting evidence includes a forward PE of 18.49x, which is reasonable for a company with 18.4% revenue growth, but the trailing PE of 25.94x suggests much of the near-term growth is already priced in. The stock's 54.36% 1-year gain and position at 91.6% of its 52-week range indicate limited near-term upside. Positively, the company's massive $5.51B TTM free cash flow and stable dividend support a floor under the stock. Analyst sentiment is cautiously positive, with recent upgrades, but the low number of covering analysts (6) suggests conviction is not widespread.
The thesis would upgrade to a Buy if the forward PE compressed below 16x (offering a clearer margin of safety) or if revenue growth sustainably accelerated above 20% while margins held firm. It would downgrade to a Sell if quarterly revenue growth decelerated below 10%, net margins contracted below 0.5%, or the stock broke below the $200 support level on high volume. Relative to its own history and the low-margin distribution sector, the stock is fairly valued to slightly overvalued, pricing in a continuation of recent strong execution.
Sign up to view all
CAH 12-Month Price Forecast
The assessment is neutral based on a clash between strong fundamentals and full valuation. The company's oligopoly position and cash generation are undeniable strengths, but the stock's 54% annual run and elevated trailing multiple suggest the easy money has been made. The forward PE of 18.5x offers a path for patient investors if earnings grow as expected. The stance would upgrade to bullish on a pullback to the $190-$200 range (improving margin of safety) or evidence of sustained margin expansion. It would turn bearish if revenue growth decelerates below 10% or technical support at $200 fails.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cardinal Health's 12-month outlook, with a consensus price target around $279.67 and implied upside of +30.0% versus the current price.
Average Target
$279.67
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$172 - $280
Analyst target range
Analyst coverage for Cardinal Health is limited, with only 6 analysts providing estimates, which is typical for a large-cap but steady-state company in a mature industry. The consensus sentiment leans bullish, as evidenced by recent institutional ratings from firms like Barclays, Wells Fargo, and Morgan Stanley maintaining 'Overweight' or 'Buy' equivalents, and Citigroup upgrading from 'Neutral' to 'Buy' in January 2026. The average target price is not explicitly provided in the data, so implied upside cannot be calculated, but the pattern of ratings suggests a positive outlook. The provided analyst data focuses on estimates, with an average EPS estimate of $17.35 and an average revenue estimate of $374.32 billion. The wide range between the low EPS estimate of $16.88 and the high of $17.96, alongside a revenue estimate range from $366.57B to $384.40B, indicates a moderate degree of uncertainty or variance in modeling assumptions among the covering analysts. This range reflects different takes on the company's ability to maintain growth momentum and manage costs in the coming periods. The recent news of a consistent quarterly dividend approval aligns with the analyst view of the company as a stable, cash-generative entity.
Bulls vs Bears: CAH Investment Factors
The evidence currently tilts bullish, primarily due to Cardinal Health's unassailable market position, accelerating revenue growth, and powerful cash generation within a defensive sector. The bear case is anchored in the stock's premium valuation after a 54% run and the inherent fragility of its low-margin business model. The single most important tension in the investment debate is whether the company's robust top-line growth (18.42% YoY) can consistently translate into sufficient bottom-line earnings to justify its elevated trailing PE multiple of 25.94x, or if margin compression will expose the valuation as stretched.
Bullish
- Dominant Oligopoly Market Position: Cardinal Health, alongside Cencora and McKesson, controls over 90% of the US pharmaceutical wholesale market. This entrenched oligopoly provides a significant competitive moat, scale advantages, and pricing power, which underpins its stable revenue stream and consistent cash generation.
- Robust Revenue Growth Acceleration: Q2 FY2026 revenue grew 18.42% year-over-year to $65.44 billion, accelerating from $60.16B in Q4 FY2025. This multi-quarter uptrend, driven by the core Pharmaceutical segment ($60.67B in Q2), demonstrates strong underlying demand and execution in a defensive sector.
- Exceptional Free Cash Flow Generation: The company generates substantial cash, with TTM free cash flow of $5.51 billion. This provides ample internal funding for dividends, share repurchases, and strategic initiatives, reinforcing its status as a stable income stock, as evidenced by the recent quarterly dividend approval.
- Strong Relative Outperformance & Low Beta: The stock has gained 54.36% over the past year, significantly outperforming the SPY's 22.2% gain, while maintaining a low beta of 0.65. This combination of strong returns with lower-than-market volatility is attractive for risk-adjusted portfolios seeking defensive growth.
Bearish
- Extremely Thin Profit Margins: The business model is characterized by razor-thin margins, with a Q2 net margin of 0.72% and a gross margin of 3.38%. This leaves the company highly sensitive to cost inflation, operational inefficiencies, or pricing pressure, which could quickly erode absolute profits.
- Valuation at High End of Historical Range: The trailing PE of 25.94x sits near the higher end of its own historical range (observed between ~14x and 42x). This suggests the market is pricing in optimistic expectations for sustained growth, leaving limited room for multiple expansion and increasing downside risk if execution falters.
- Technical Overextension Near 52-Week High: Trading at $214.05, the stock is near cycle highs, positioned at 91.6% of its 52-week range ($120.72 to $233.60). Recent momentum shows fatigue with a -5.43% 1-month decline, suggesting limited near-term upside and potential for a deeper correction toward the $200 support level.
- Negative Shareholder Equity & ROE: The company has negative shareholder equity, leading to a negative ROE of -56.13% and a negative P/B ratio. While an accounting artifact from accumulated deficits, it complicates traditional equity valuation and indicates a history of retained earnings deficits.
CAH Technical Analysis
The stock is in a sustained, powerful uptrend, evidenced by a 1-year price change of +54.36%, significantly outperforming the broader market's +22.2% gain. As of the latest close of $214.05, the price is trading approximately 91.6% of its 52-week range ($120.72 to $233.60), positioning it near cycle highs, which signals strong momentum but also raises concerns about potential overextension and limited near-term upside. The stock's beta of 0.65 indicates it is 35% less volatile than the market, a characteristic of a defensive name, which is notable given its substantial price appreciation. Recent momentum shows signs of consolidation and potential short-term fatigue, with the stock down -5.43% over the past month, diverging from the powerful longer-term uptrend. However, the 3-month change remains positive at +4.05%, which still outpaces the SPY's -4.0% return over the same period, suggesting the pullback may be a healthy correction within the broader uptrend rather than a reversal. The relative strength metrics confirm this mixed picture, with a -1.15 relative strength over one month but a strong +8.05 over three months, indicating the stock is taking a breather after its significant run. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $233.60 and primary support at the 52-week low of $120.72. A decisive breakout above the $233.60 resistance would signal a continuation of the bull trend, while a sustained breakdown below recent support around $200 could indicate a deeper correction is underway. The stock's low beta of 0.65 implies it should exhibit lower volatility than the market, which is important for risk-adjusted positioning, though the recent 1-month drawdown of -13.07% shows it is not immune to sector or broad market sell-offs.
Beta
0.65
0.65x market volatility
Max Drawdown
-13.1%
Largest decline past year
52-Week Range
$121-$234
Price range past year
Annual Return
+72.1%
Cumulative gain past year
| Period | CAH Return | S&P 500 |
|---|---|---|
| 1m | -3.2% | -0.3% |
| 3m | +6.2% | -2.0% |
| 6m | +37.1% | +3.5% |
| 1y | +72.1% | +36.2% |
| ytd | +4.6% | -0.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CAH Fundamental Analysis
Revenue growth is robust and accelerating, with Q2 FY2026 revenue reaching $65.44 billion, representing a significant 18.42% year-over-year increase. This growth is part of a multi-quarter uptrend, as revenue has climbed sequentially from $60.16B in Q4 FY2025 to $64.01B in Q1 FY2026, indicating strong underlying demand. The Pharmaceutical segment, contributing $60.67 billion in the latest period, is the primary growth driver, while the Medical segment (GMPD) at $3.26 billion and 'Other' at $1.72 billion represent smaller, more specialized operations. Profitability is stable but characterized by razor-thin margins typical of the distribution business. Net income for Q2 FY2026 was $471 million, translating to a net margin of just 0.72%. The gross margin was 3.38% for the quarter, consistent with the industry model of high volume and low per-unit profit. Operating income was $707 million, yielding an operating margin of 1.08%. While absolute profits are healthy, these single-digit margin percentages highlight the operational efficiency required and the sensitivity to cost pressures. The balance sheet and cash flow picture is strong, with the company generating substantial free cash flow. Trailing twelve-month free cash flow stands at $5.51 billion, providing ample internal funding for growth initiatives, dividends, and share repurchases. The current ratio is 0.94, indicating adequate but not excessive liquidity for meeting short-term obligations. Notably, the return on equity (ROE) is negative at -56.13%, which is an accounting artifact likely due to negative shareholder equity from accumulated deficits, but this is offset by a positive return on assets (ROA) of 3.50%, demonstrating efficient use of its asset base to generate earnings.
Quarterly Revenue
$65.4B
2025-12
Revenue YoY Growth
+0.18%
YoY Comparison
Gross Margin
+0.03%
Latest Quarter
Free Cash Flow
$5.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CAH Overvalued?
Given a positive net income of $471 million in the latest quarter, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 25.94x, while the forward PE is lower at 18.49x, indicating the market expects earnings growth to continue, which aligns with the observed revenue acceleration and stable margins. Compared to sector averages, Cardinal Health trades at a significant premium based on its sales multiple. Its Price-to-Sales (PS) ratio of 0.18 is a key metric for low-margin distributors. While a direct industry average PS is not provided in the data, the company's EV-to-Sales of 0.23 suggests the market values its revenue stream. The premium is likely justified by its entrenched market position within the oligopolistic US pharmaceutical wholesale industry, consistent cash generation, and defensive characteristics. Historically, the stock's current trailing PE of 25.94x sits above its own recent historical range observed in the provided data, where it has fluctuated between approximately 14x and 42x over the past several quarters. This positioning near the higher end of its historical band suggests the market is pricing in optimistic expectations for sustained growth and margin stability. The forward PE of 18.49x, however, points to anticipated earnings expansion that could bring the valuation more in line with historical norms if achieved.
PE
25.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -450x~73x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the company's ultra-thin margins and balance sheet structure. With a net margin of just 0.72% and a gross margin of 3.38%, even minor cost increases or pricing pressures could disproportionately impact profitability. The negative shareholder equity, resulting in a negative ROE of -56.13%, is an accounting red flag, though mitigated by a positive ROA of 3.50%. Revenue concentration is also a risk, with the Pharmaceutical segment comprising over 92% of total sales, making the company highly dependent on the dynamics of drug distribution.
Market & Competitive Risks include valuation compression, given the stock trades at a trailing PE of 25.94x, which is at the higher end of its historical range. As a low-beta (0.65) defensive stock that has significantly outperformed, it is vulnerable to sector rotation out of healthcare or a de-rating if growth decelerates. Competitive risks are moderated by the oligopoly structure, but regulatory scrutiny of drug pricing or distribution practices remains a persistent external threat. The stock's recent 1-month drawdown of -13.07% demonstrates it is not immune to broader market sell-offs.
The Worst-Case Scenario involves a combination of margin contraction due to inflationary cost pressures, a slowdown in pharmaceutical volume growth, and a broader market de-rating of defensive stocks. This could trigger a reversion toward the lower end of its historical PE range and a test of key technical support levels. A realistic downside could see the stock fall -35% to -40% from current levels, retesting the $120-$130 range (near its 52-week low of $120.72), which would represent a significant loss for investors buying at the cycle high.
FAQ
The key risks are, in order of severity: 1) Margin Risk: Ultra-thin net (0.72%) and gross (3.38%) margins make profits highly vulnerable to cost pressures. 2) Valuation Risk: Trading near 52-week highs with a elevated trailing PE, the stock is prone to a significant correction if growth slows. 3) Concentration Risk: Over 92% of revenue comes from pharmaceutical distribution, exposing the company to sector-specific headwinds. 4) Financial Statement Risk: Negative shareholder equity and ROE, while an accounting artifact, are unusual for a large-cap company and can deter some investors.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $210 and $235, assuming revenue growth moderates but remains healthy and the forward PE of ~18x holds. The Bull Case (25% probability) targets $245 to $260 on sustained high growth and a breakout above all-time highs. The Bear Case (15% probability) warns of a drop to $160-$190 if margins contract and growth disappoints. The base case is most likely, anchored on the company's stable market position and cash flow, but with limited multiple expansion from current levels.
CAH appears fairly valued to slightly overvalued based on its own history. The trailing PE of 25.94x is at the higher end of its observed historical range (~14x to 42x), suggesting the market is pricing in strong continued growth. The forward PE of 18.49x, based on an average EPS estimate of $17.35, is more reasonable and implies expected earnings growth. Compared to sector peers, its Price-to-Sales ratio of 0.18 is a key metric for distributors, but without a direct peer average, the valuation is best assessed as full but not extreme, assuming the company executes on its growth trajectory.
CAH is a good buy for a specific investor profile: those seeking a defensive, low-volatility holding in the healthcare sector with a dividend. However, after a 54% gain in one year, the stock is fairly valued to slightly overvalued (trailing PE of 25.9x), limiting near-term upside. The massive free cash flow ($5.51B TTM) and dominant market position provide a solid foundation, but new money may want to wait for a pullback toward the $190-$200 range to improve the risk/reward. It is less suitable for aggressive growth investors.
CAH is primarily suitable for a long-term investment horizon of 3-5 years. Its low beta (0.65), defensive sector, and dividend align with a buy-and-hold income/growth strategy. The stock's recent technical volatility and full valuation make it less ideal for short-term trading, as near-term catalysts for major upside appear limited. A long-term horizon allows investors to benefit from the company's entrenched market position and consistent cash generation while riding out potential volatility. A minimum holding period of 12-18 months is suggested to allow the fundamental story to play out.